LM350-01-101: Evaluating how safe and effective the targeted drug LM-350 is in people with advanced solid cancers who have progressed on prior treatment or have no standard treatment availableA Phase I/II, First-in-Human (FIH), Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-350 in Patients With Advanced Solid Tumors

Exclusion

1. Participate in any other clinical trial within 28 days prior to 1st dosing of LM-350.
2. Subjects who have received treatment with the same targeting.
3. Subjects who have received the following anti-tumor treatments within the specified time periods prior to the first dosing of LM-350.
4. Any adverse event from prior anti-tumour therapy has not yet recovered to ≤ grade 1 of CTCAE v5.0.
5. Subjects with uncontrolled tumour-related pain.
6. Subjects with known central nervous system (CNS) or meningeal metastasis.
7. Subjects who have clinically uncontrollable third-space fluid accumulation.
8. Subjects who experienced grade 3 or higher hypersensitivity to the treatment that contains monoclonal antibody.
9. Subjects who take systemic corticosteroids (≥ 10 mg/day of prednisone or equivalents) or other systemic immunosuppressive medications within 2 weeks prior to the first dose of LM-350.
10. Has a history of (noninfectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.
11. Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses, and any autoimmune, or prior pneumonectomy.
12. Use of any live attenuated vaccines within 28 days prior to 1st dosing of LM-350.
13. Current unstable of full-dose oral or parenteral anticoagulants or thrombolytic agents for > 2 weeks prior to the first dose of LM-350.
14. Subjects who received major surgery or interventional treatment within 28 days prior to 1st dosing of LM-350.
15. Subjects who have severe cardiovascular disease.
16. Subjects who have uncontrolled or severe illness.
17. Subjects who have a history of immunodeficiency disease.
18. HIV infection, active infection including tuberculosis, HBV and HCV infection.
19. Subjects who have other active malignancies which are likely to require the treatment.
20. Spinal cord compression, symptomatic and unstable brain metastases.
21. Child-bearing potential female who have positive results in pregnancy test or are lactating.
22. Subjects who have psychiatric illness or disorders that may preclude study compliance.
23. Subject who is judged as not eligible to participate in this study by the investigator.